Brasada Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brasada Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,000	Closed	-$14K	–	335
2018 Q1	$14K	Hold	1,000	–	–	﹤0.01%	225
2017 Q4	$15K	Buy	+1,000	New	+$14K	0.01%	227

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Brasada Capital Management's HZNP Position: Q2 2018 in Review

Brasada Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2018, closing a stake of 1,000 shares — an estimated $14K sold.

Brasada Capital Management first reported a position in HZNP in Q4 2017 and held it in 2 quarters. The position peaked at $15K in Q4 2017. 204 funds tracked by Wall St. Rank hold HZNP as of Q2 2018.

Brasada Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2018 after selling out during the quarter.
Brasada Capital Management sold 1,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2018, an estimated $14K.
Brasada Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 2 quarters.
Brasada Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $15K in Q4 2017.
204 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2018.

Based on Brasada Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.